| Ildiko Hegyvary Thomas, MD | |
|
11511 Ne 10th St, Bellevue, WA 98004-8578 | |
| (425) 502-3000 | |
| Not Available |
| Full Name | Ildiko Hegyvary Thomas |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 11511 Ne 10th St, Bellevue, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093825069 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD00048280 (Washington) | Primary |
| Entity Name | Kaiser Foundation Health Plan Of Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396810701 PECOS PAC ID: 9032022579 Enrollment ID: O20031112000454 |
News Archive
Although several monoclonal antibodies against the SARS-CoV-2 spike protein have been developed and clinically tested, little is known about antibodies to the nucleocapsid protein. In a paper published recently in the journal Nature Communications, researchers report a human monoclonal antibody that targets the nucleocapsid protein.
Boxers and mixed martial arts fighters may have markers of long-term brain injury in their blood, according to a study released today that will be presented at the American Academy of Neurology's Sports Concussion Conference in Jacksonville, Fla., July 14 to 16, 2017.
Concert Pharmaceuticals, Inc. and Fast Forward, LLC, the National Multiple Sclerosis Society's subsidiary devoted to bridging the gap between research and drug development, today announced a new collaboration to fund the preclinical advancement of C-21191, a deuterium-modified subtype-selective GABAA modulator developed by Concert with the therapeutic potential of treating spasticity and pain in multiple sclerosis (MS).
Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today reported preclinical data with ASG-5ME, an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors. In models of human prostate and pancreatic cancer, ASG-5ME was found to have potent and long lasting antitumor activity. The findings were presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C.
Eye masks and earplugs could help hospital patients get a better night's sleep. Researchers writing in BioMed Central's open access journal Critical Care investigated their effect on sleep quality in a simulated intensive care environment.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ildiko Hegyvary Thomas, MD 11511 Ne 10th St, Bellevue, WA 98004-8578 Ph: (425) 502-3000 | Ildiko Hegyvary Thomas, MD 11511 Ne 10th St, Bellevue, WA 98004-8578 Ph: (425) 502-3000 |
News Archive
Although several monoclonal antibodies against the SARS-CoV-2 spike protein have been developed and clinically tested, little is known about antibodies to the nucleocapsid protein. In a paper published recently in the journal Nature Communications, researchers report a human monoclonal antibody that targets the nucleocapsid protein.
Boxers and mixed martial arts fighters may have markers of long-term brain injury in their blood, according to a study released today that will be presented at the American Academy of Neurology's Sports Concussion Conference in Jacksonville, Fla., July 14 to 16, 2017.
Concert Pharmaceuticals, Inc. and Fast Forward, LLC, the National Multiple Sclerosis Society's subsidiary devoted to bridging the gap between research and drug development, today announced a new collaboration to fund the preclinical advancement of C-21191, a deuterium-modified subtype-selective GABAA modulator developed by Concert with the therapeutic potential of treating spasticity and pain in multiple sclerosis (MS).
Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today reported preclinical data with ASG-5ME, an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors. In models of human prostate and pancreatic cancer, ASG-5ME was found to have potent and long lasting antitumor activity. The findings were presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C.
Eye masks and earplugs could help hospital patients get a better night's sleep. Researchers writing in BioMed Central's open access journal Critical Care investigated their effect on sleep quality in a simulated intensive care environment.
› Verified 4 days ago
Eric Albert Gustafson, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2700 Northup Way, Bellevue, WA 98004 Phone: 425-827-4600 | |
Dr. Arlene Elizabeth Ritzen, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1900 116th Ave Ne, Bellevue, WA 98004 Phone: 425-453-0404 | |
Dr. Emily Susan Showman, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3633 136th Place Se, Suite #110, Bellevue, WA 98006 Phone: 425-747-7202 Fax: 425-643-0635 | |
Bill M Fournarakis, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2700 Northup Way, Bellevue, WA 98004 Phone: 425-827-4600 Fax: 425-828-2256 | |
Irene Hwang, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3633 136th Place Se, Suite #110, Bellevue, WA 98006 Phone: 425-747-7202 Fax: 425-643-0635 | |
Pamela Laborde, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3633 136th Place Se, Suite #110, Bellevue, WA 98006 Phone: 425-747-7202 Fax: 425-643-0635 |